BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|April 2, 2003
- Pharmaceutical Technology-04-02-2003
- Volume 27
- Issue 4
Outsourcing Outlook
Author(s)Jim Miller
As demand for contract services slows down, contractors restructure themselves and the industry.
Advertisement
Articles in this issue
over 23 years ago
April 2003over 23 years ago
Identification of Out-of-Trend Stability Resultsover 23 years ago
Overhauling Compliance and GMPsAdvertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
3
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
4
Ask the Expert: Choosing Ingredient Suppliers
5